This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AstraZeneca Falls on Drug Setback

Updated from 8:35 a.m.

Shares in the U.K-based drugmaker AstraZeneca (AZN - Get Report) fell Monday after an advisory committee of the Food and Drug Administration late Friday dealt a staggering blow to the company's experimental blood thinner Exanta, saying the risks of liver damage outweighed the benefits.

The panel rejected AstraZeneca's entire application that Exanta be approved for three uses related to preventing blood clots, Reuters reported Friday.

The FDA is expected to act on the panel's recommendations by late October. The agency doesn't have to follow its advisers' suggestions, but it usually does so.

Shares were off $1.60, or 3.7%, to $42.14.

AstraZeneca had asked the FDA to approve the drug for preventing blood clots in veins for patients undergoing knee-replacement surgery; preventing stroke and other clot-induced complications of the erratic heartbeat known as atrial fibrillation; and long-term prevention of blood clots in veins after a patient has gotten a standard blood clot treatment.

But once the advisory panel rejected the knee-replacement-surgery application, it was clear that Exanta was in trouble. Analysts had viewed knee surgery as Exanta's best chance because the European Union has approved the drug for preventing blood clots after elective knee and hip surgeries.

In the company's U.S. application, knee surgery would have only required, at most, 12 days of treatment with the drug, whereas the other indications would have required long-term use of Exanta.

In addition, the FDA panel rejected as inadequate the company's proposed monitoring plan to protect Exanta users against liver damage.

The advisory committee voted after markets had closed. AstraZeneca's stock closed Friday at $43.74, losing 66 cents, or 1.5%, on trading volume that was 6 times the daily average. But in after-hours trading, the stock was down another $1.29, or 3.3%.

On Thursday, an unfavorable FDA staff report used as guidance for the advisory committee sent the stock down 5.6% on trading volume that was 11 times greater than average. The report raised significant concerns about liver damage stemming from long-term use of Exanta.

AstraZeneca was hoping that the advisory committee would enable Exanta to become the first new oral anticoagulant in more than 60 years in the U.S . The "gold standard" is warfarin, a pill sold by several generic companies and also sold under the brand name Coumadin by Bristol-Myers Squibb (BMY). Exanta is easier to administer than Coumadin, which requires periodic blood tests to measure its effectiveness. The AstraZeneca drug doesn't interact with as many drugs and foods as Coumadin does.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AZN $71.32 0.00%
MRK $56.88 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs